SELLAS Life Sciences Group Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.97. In total, the insiders bought 2 830 450 and sold 33 402 SLS shares in the last 100 trades.

Insider Power

(Last 100 transactions)
94.97
Buy 2 830 450 Shares
Sell 33 402 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 20, 2024 Common Stock Buy Cicic Dragan 0
Jun 20, 2024 Stock Option (Right to Buy) Buy Cicic Dragan 35 000
Jun 20, 2024 Stock Option (Right to Buy) Buy Cicic Dragan 47 250
Jun 20, 2024 Stock Option (Right to Buy) Buy Cicic Dragan 48 750
Jun 20, 2024 Stock Option (Right to Buy) Buy Cicic Dragan 55 000
Jun 20, 2024 Stock Option (Right to Buy) Buy Cicic Dragan 65 000
Jan 22, 2024 Common Stock Buy Stergiou Angelos M. 159 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Stergiou Angelos M. 238 500
Jan 22, 2024 Common Stock Buy Scheinberg David A 6 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Scheinberg David A 10 000
Jan 22, 2024 Common Stock Buy Wood Barbara A 35 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Wood Barbara A 50 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Kalin Katherine Bach 10 000
Jan 22, 2024 Common Stock Buy Kalin Katherine Bach 6 000
Jan 22, 2024 Common Stock Buy Wasman Jane 6 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Wasman Jane 10 000
Jan 22, 2024 Common Stock Buy Francomano Robert 20 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Francomano Robert 30 000
Jan 22, 2024 Common Stock Buy Varian John 6 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Varian John 10 000
Jan 22, 2024 Common Stock Buy Van Nostrand Robert L 6 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Van Nostrand Robert L 10 000
Jan 22, 2024 Common Stock Buy Burns John Thomas 47 000
Jan 22, 2024 Stock Option (Right to Buy) Buy Burns John Thomas 75 000
Dec 06, 2023 Class A Common Stock Sell Wood Barbara A 4 119
Click to get the best stock tips daily for free!

About SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group. SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cance... SLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT